BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tricot T, Verfaillie CM, Kumar M. Current Status and Challenges of Human Induced Pluripotent Stem Cell-Derived Liver Models in Drug Discovery. Cells 2022;11:442. [DOI: 10.3390/cells11030442] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Anne van Os E, Cools L, Eysackers N, Szafranska K, Smout A, Verhulst S, Reynaert H, Mccourt P, Mannaerts I, van Grunsven LA. Modelling fatty liver disease with mouse liver-derived multicellular spheroids. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121817] [Reference Citation Analysis]
2 Liu P, Zhou Q, Li J. Integrated Multi-Omics Data Analysis Reveals Associations Between Glycosylation and Stemness in Hepatocellular Carcinoma. Front Oncol 2022;12:913432. [DOI: 10.3389/fonc.2022.913432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Carberry CK, Ferguson SS, Beltran AS, Fry RC, Rager JE. Using liver models generated from human-induced pluripotent stem cells (iPSCs) for evaluating chemical-induced modifications and disease across liver developmental stages. Toxicology in Vitro 2022. [DOI: 10.1016/j.tiv.2022.105412] [Reference Citation Analysis]
4 Nikokiraki C, Psaraki A, Roubelakis MG. The Potential Clinical Use of Stem/Progenitor Cells and Organoids in Liver Diseases. Cells 2022;11:1410. [DOI: 10.3390/cells11091410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Wei L, Xia S, Li Y, Qi Y, Wang Y, Zhang D, Hua Y, Luo S. Application of hiPSC as a Drug Tester Via Mimicking a Personalized Mini Heart. Front Genet 2022;13:891159. [DOI: 10.3389/fgene.2022.891159] [Reference Citation Analysis]